Enzolytics Inc (ENZC)

[falon]

ENZC

Enzolytics, Inc. Announces the Completion of the 2020 and 2021 Audited Financials
ACCESSWIRE - Mon Dec 19, 2022
COLLEGE STATION, TX / ACCESSWIRE / December 19, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).

Enzolytics, Inc. announces the completion of the 12/31/2020 and 12/31/2021 audited financials. The Company has refiled the 12/31/2021 Disclosure Statement reflecting the completion of the audit covering 2020 and 2021. These filings provide investors with detailed audited information about the Company's operations, business strategies, and financials. The reports will assist the Company's investors in understanding the Company's operations and its focus. In conjunction with the completion of the audits, and as part of the Company's ongoing commitment to transparency and accountability, Enzolytics is planning to become a fully reporting 34 Act Filer with the SEC.

No specific date given as to when ENZC will become a fully reporting 34 Act Filer with the SEC.

The Company CEO, Charles Cotropia, said, "Enzolytics is focused on accelerating the growth of our clinical products, technology platforms, and multiple applications now in progress. The Company is making substantial advancement in its three synergistic therapeutic platforms generating multiple clinical products for human and veterinary use. Over the last two years, we have focused on advancing our research and development and strengthening our Intellectual Property portfolio covering our technologies. As a result, we have made significant strides and substantive progress on multiple fronts. Our completion of a two-year audit is just one of the many objectives we have set and achieved.

What are these three synergistic therapeutic platforms?

IPF Immune

ITV-1 anti-HIV therapeutic

fully feline Monoclonal Antibodie

"In the year ahead, Enzolytics will share additional plans regarding our technologies, planned partnerships, and projects, as well as achievements in each of our therapeutics platforms. We have full faith in our long-term vision and mission and are confident in our team's ability to achieve set goals."

What are the plans regarding our technologies?

Who are these planned partnerships?

ENZC already have a relationship/collaboration with 2 billion dollar companies:

As of March 2023 Samsung Biologics has a market cap of $45.33 Billion. This makes Samsung Biologics the world's 380th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.

Twist Bioscience Enterprise Value is comparatively stable at the moment as compared to the past year. Twist Bioscience reported Enterprise Value of 1.94 Billion in 2022. Tangible Asset Value is likely to gain to about 1 B in 2023, whereas Free Cash Flow is likely to drop (209 M) in 2023.

Abveris (Twist Boston) whom ENZC `is working with was acquired by Twist in November 2021 for 190 million dollars.

What projects?

The Company COO, Dr. Gaurav Chandra, noted, "At Enzolytics, innovation is driven through our ecosystems with a collective mission to accelerate innovation. Our A.I. platform drives the Company's drug discovery and development and represents an overall strategy to produce therapeutics covered by an all-encompassing Intellectual Property portfolio. We take pride in strengthening our I.P. portfolio covering the anti-virus therapeutics, their method of production, diagnostics and prognostics. Our application of Artificial Intelligent to drug formulation and creation has made possible our move beyond big pharma's monoclonal antibody discovery and development. Enzolytics continues to forge ahead with the immediate strategy to identify novel biomarkers and therapeutic targets, design innovative diagnostic and prognostic tests, and expand the Company's Patent portfolio.

"In addition, Enzolytics' long-term plan is to be a serious contender in the personalized medicine market. The Company acknowledges the importance of an all-encompassing One Health approach recognizing the link between the health of people, animals, and the environment. As part of that approach, we identified conserved sites for Monkey Pox (https://www.nasdaq.com/press-release/enzolytics-announces-the-discovery-of-conserved-target-sites-on-the-monkeypox-virus) 2 weeks before WHO declared it a Global Public Health Emergency. Enzolytics continues to partner and engage with technology, genetics, veterinary centers, diagnostic and regulatory companies applying that strategy in each of these areas."


There is a lot going on with ENZC and although we all want information now, the company has shared as much as they can and are probably under constraint due to the NDAs.

EZNC usually put on a press release at least once a month or more often if information needs to be shared.

There are a lot of unknowns to us shareholders at the moment however when the veil is lifted I'm hopeful ENZC will "shock the world" just like UCONN Huskies did back 1999.

It is "March Madness" time and we may get some very much anticipated madness from ENZC

Go UCONN

Go ENZC

SHOCK the WORLD!!!